Literature DB >> 23319768

The genomic landscape of breast cancer as a therapeutic roadmap.

Matthew J Ellis1, Charles M Perou.   

Abstract

The application of high-throughput techniques to profile DNA, RNA, and protein in breast cancer samples from hundreds of patients has profoundly increased our knowledge of the disease. The etiologic events that drive breast cancer are finally coming into focus and should be used to set priorities for clinical trials. In this Prospective, we summarize some of the headline conclusions from 6 recent breast cancer "omics profiling" articles in Nature, with an emphasis on the implications for systemic therapy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23319768      PMCID： PMC3553590          DOI： 10.1158/2159-8290.CD-12-0462

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  44 in total

1.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

Review 2.  MDM2 inhibitors for cancer therapy.

Authors:  Lyubomir T Vassilev
Journal:  Trends Mol Med       Date:  2006-11-28       Impact factor: 11.951

3.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Authors:  Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

4.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Authors:  Katherine Stemke-Hale; Ana Maria Gonzalez-Angulo; Ana Lluch; Richard M Neve; Wen-Lin Kuo; Michael Davies; Mark Carey; Zhi Hu; Yinghui Guan; Aysegul Sahin; W Fraser Symmans; Lajos Pusztai; Laura K Nolden; Hugo Horlings; Katrien Berns; Mien-Chie Hung; Marc J van de Vijver; Vicente Valero; Joe W Gray; René Bernards; Gordon B Mills; Bryan T Hennessy
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 5.  Targeting the MDM2-p53 interaction for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

6.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

Authors:  Robert J Crowder; Chanpheng Phommaly; Yu Tao; Jeremy Hoog; Jingqin Luo; Charles M Perou; Joel S Parker; Melinda A Miller; David G Huntsman; Li Lin; Jacqueline Snider; Sherri R Davies; John A Olson; Mark A Watson; Anthony Saporita; Jason D Weber; Matthew J Ellis
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

8.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.

Authors:  Sanjeev Shangary; Dongguang Qin; Donna McEachern; Meilan Liu; Rebecca S Miller; Su Qiu; Zaneta Nikolovska-Coleska; Ke Ding; Guoping Wang; Jianyong Chen; Denzil Bernard; Jian Zhang; Yipin Lu; Qingyang Gu; Rajal B Shah; Kenneth J Pienta; Xiaolan Ling; Sanmao Kang; Ming Guo; Yi Sun; Dajun Yang; Shaomeng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-03       Impact factor: 11.205

9.  The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

Authors:  Jason I Herschkowitz; Xiaping He; Cheng Fan; Charles M Perou
Journal:  Breast Cancer Res       Date:  2008-09-09       Impact factor: 6.466

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245
View more
  91 in total

Review 1.  Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.

Authors:  Toshifumi Wakai; Pankaj Prasoon; Yuki Hirose; Yoshifumi Shimada; Hiroshi Ichikawa; Masayuki Nagahashi
Journal:  Int J Clin Oncol       Date:  2018-12-04       Impact factor: 3.402

Review 2.  Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.

Authors:  D Merino; S W Lok; J E Visvader; G J Lindeman
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

Review 3.  Regulation of mammary epithelial cell homeostasis by lncRNAs.

Authors:  Amy N Shore; Jeffrey M Rosen
Journal:  Int J Biochem Cell Biol       Date:  2014-03-26       Impact factor: 5.085

Review 4.  Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.

Authors:  Ashley G Rivenbark; Siobhan M O'Connor; William B Coleman
Journal:  Am J Pathol       Date:  2013-08-27       Impact factor: 4.307

Review 5.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

6.  Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.

Authors:  Matthew J Ellis; Michael Gillette; Steven A Carr; Amanda G Paulovich; Richard D Smith; Karin K Rodland; R Reid Townsend; Christopher Kinsinger; Mehdi Mesri; Henry Rodriguez; Daniel C Liebler
Journal:  Cancer Discov       Date:  2013-10       Impact factor: 39.397

7.  A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.

Authors:  Lijun Cheng; Bryan P Schneider; Lang Li
Journal:  J Am Med Inform Assoc       Date:  2016-04-23       Impact factor: 4.497

8.  miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC.

Authors:  Xiaowei Shen; Jiaqi Lei; Lei Du
Journal:  Exp Ther Med       Date:  2019-11-12       Impact factor: 2.447

Review 9.  Intrinsic cancer subtypes--next steps into personalized medicine.

Authors:  Cristina Santos; Rebeca Sanz-Pamplona; Ernest Nadal; Julieta Grasselli; Sonia Pernas; Rodrigo Dienstmann; Victor Moreno; Josep Tabernero; Ramon Salazar
Journal:  Cell Oncol (Dordr)       Date:  2015-01-14       Impact factor: 6.730

10.  Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients.

Authors:  Agnieszka Kolacinska; Jan Morawiec; Zofia Pawlowska; Janusz Szemraj; Bożena Szymanska; Beata Malachowska; Zbigniew Morawiec; Alina Morawiec-Sztandera; Lukasz Pakula; Robert Kubiak; Izabela Zawlik
Journal:  DNA Cell Biol       Date:  2014-05-27       Impact factor: 3.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.